Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine
(Armenpress)- The U.S. Food and Drug Administration (FDA) completed its review of Noubar Afeyan’s biotech firm Moderna’s Investigational New Drug (IND) application for its novel coronavirus (SARS-CoV-2 or COVID-19) vaccine candidate (mRNA-1273) allowing it to proceed to Phase 2 study, expected to begin shortly, the company said in a news release.
The Phase 3 study of mRNA-1273 is expected to begin in early summer of 2020.
The company is also preparing for a Phase 3 trial in the summer, and hopes to have the final vaccine approved “as soon as 2021.”
More than a dozen companies are involved in a global race to develop a coronavirus vaccine.